Evidence map›Paper›PMID 30819593›Full record

ReviewSchizophrenia research2020

P300 as an index of transition to psychosis and of remission: Data from a clinical high risk for psychosis study and review of literature.

Yingying Tang, Junjie Wang, Tianhong Zhang, Lihua Xu, Zhenying Qian, Huiru Cui, Xiaochen Tang, Huijun Li, Susan Whitfield-Gabrieli, Martha E Shenton and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Schizophrenia research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. P300 in schizophrenia: Then and now.Biological psychology · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Neural Circuitry of Salience and Reward Processing in Psychosis.Biological psychiatry global open science · 2023
    Review
  17. A redux of schizophrenia research in 2021.Schizophrenia research · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yingying TangShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Key Laboratory of Embedded System and Service Computing (Tongji University), Ministry of Education, Shanghai 201804，China.
Junjie WangShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Institute of Mental Health, Suzhou Psychiatric Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, Jiangsu, China.
Tianhong ZhangShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Lihua XuShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Zhenying QianShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Huiru CuiShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Xiaochen TangShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Huijun LiDepartment of Psychology, Florida A&M University, Tallahassee, FL, USA.
Susan Whitfield-GabrieliMcGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Martha E ShentonPsychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130, USA; Research and Development, Veterans Affairs Boston Healthcare System, Brockton Division, Brockton, MA, USA.
Larry J SeidmanDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA.
Robert W McCarleyHarvard Medical School, Department of Psychiatry, Veterans Administration Medical Center, MA 02130, USA.
Matcheri S KeshavanDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA.
William S StoneDepartment of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02130, USA.
Jijun WangShanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), Chinese Academy of Science, China; Institute of Psychology and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China. Electronic address: jijunwang27@163.com.
Margaret A NiznikiewiczHarvard Medical School, Department of Psychiatry, Veterans Administration Medical Center, MA 02130, USA.

Funding

Identifying mechanisms of response to therapeutic intervention in clinical high risk (CHR) for psychosis: a bridge to treatmentR01MH111448 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, HUIJUN, NIZNIKIEWICZ, MARGARET A · 2016 to 2023
$4.4M
Validating Biomarkers for the Prodrome and Transition to Psychosis in ShanghaiR01MH101052 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, HUIJUN, MCCARLEY, ROBERT W · 2013 to 2015
$600k
NIMH NIH HHS R01 MH101052NIMH NIH HHS R01 MH111448
6 · The paper itself

Abstract

Auditory P300 oddball and novel components index working memory operations and salience processing, respectively, and are regarded as biomarkers of neurocognitive changes in both chronic and first-episode schizophrenia. Much less is known about whether P300 abnormalities exist in individuals at clinical high risk for psychosis (CHR) and if they are predictors of both transition to psychosis and remission from symptoms. One hundred and four CHR and 69 healthy control individuals (HC) completed P300 oddball paradigm, and 131 CHR and 69 HC subjects completed P300 novel paradigm. All CHR subjects were followed up for one year and stratified into CHR converters (CHRC) and non-converters (CHR-NC), with CHR-NC further stratified into remitted and non-remitted subgroups. Between-group comparisons of P300 oddball and novel amplitude and latency were performed among CHRC, CHR-NC and HC, as well as among CHRC, non-remitted CHR, remitted CHR and HC. CHR converters had lower fronto-central P300 novel amplitude as well as marginally lower P300 oddball amplitude relative to HC. When CHR non-converters were stratified into remitted and non-remitted subgroups, P300 novel amplitude in remitted CHR subjects was comparable to HC, and it was higher than that in CHR subjects who converted to psychosis or who did not remit. Thus, reduced P300 novel amplitude indexing impaired salience processing marked both conversion to psychosis and remission from psychotic symptoms.

Indexed as

Psychotic DisordersSchizophreniaHumansClinical high risk for psychosisP300 novelP300 oddballRemission from psychotic symptomsTransition to psychosis

Identifiers

PMID30819593
PMCPMC6708777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.